Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.

Authors not listed

Universitaire Ziekenhuizen KU Leuven · 2026

Abstract

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2026). The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level. <em>Universitaire Ziekenhuizen KU Leuven</em>. https://clinicaltrials.gov/study/NCT07666113
Vancouver
Anonymous. The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level. Universitaire Ziekenhuizen KU Leuven. 2026.
BibTeX
@misc{anon2026TheDia, title = {The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.}, author = {Anonymous}, journal = {Universitaire Ziekenhuizen KU Leuven}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings